2025 US Healthcare & Life Sciences Transactions Outlook

Healthcare and life sciences transaction activity in the United States is expected to rebound in 2025, driven by efforts to enhance technological capabilities, tackle labor and operational challenges, and capitalize on new opportunities brought on by stabilizing interest rates.

However, regulatory uncertainty caused by the new administration and US Congress, increasing financial pressures, and strategic misalignment could temper industry momentum.

Key Findings

Hover over the images below to discover more:

BRG’s US Healthcare & Life Sciences Transactions Outlook adds depth to this emerging picture, drawing on responses from a survey of 150 executives and corporate decision-makers at US provider, payer, and life sciences organizations. Insights from in-depth interviews with prominent industry professionals and BRG experts complement these findings.

While 2025 presents abundant transaction opportunities for payers, providers, and life sciences organizations, challenges remain. This report offers readers critical insights into key focus areas, deal types, drivers, and hurdles ahead.

We encourage you to review our full report and chart pack to gain additional and valuable insights from our comprehensive survey findings, and download the executive overview for a concise summary of key findings.